COMP <GO>
TEVA vs ONC // EV/EBITDA & P/E VALUATION
Teva Pharmaceutical Industries Limited (NYSE) VS. BeOne Medicines Ltd. (NASDAQ) • 15-METRIC TALLY: TEVA 7
— ONC 6
▲ EV/EBITDA & P/E VALUATION LEADER: TEVA
LAST: $42.09 (+1.50%) • MKT CAP: $48.32B
valuation
20.8x
LAST: $370.33 (-0.33%) • MKT CAP: $42.25B
valuation
63.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TEVA VS. ONC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TEVA | ONC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.80% | 87.50% | -35.70 | ONC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 10.50% | -1.10 | ONC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.8x | 63.9x | -43.10 | TEVA | /valuation <GO> |
| Free Cash Flow Yield | 1.81% | 2.23% | -0.42 | ONC | /fcf-yield <GO> |
| Operating Margin | 12.50% | 8.40% | +4.10 | TEVA | /operating-margins <GO> |
| Net Profit Margin | 8.20% | 5.40% | +2.80 | TEVA | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 40.20% | -35.90 | ONC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.02 | 6.68 | -5.66 | ONC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | ONC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.6 | 53.6 | +5.00 | TEVA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.98 | +0.02 | TEVA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.9x | 123.6x | -91.70 | TEVA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $48.32B | $42.25B | $6.08B | TEVA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TEVA REV | ONC REV | TEVA GROSS % | ONC GROSS % | TEVA FCF | ONC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.26B | $5.34B | 51.8% | 87.5% | $872.4M | $941.7M |
| FY 2024 | $16.54B | $3.81B | 48.7% | 84.4% | $502.5M | -$633.3M |
| FY 2023 | $15.85B | $2.46B | — | — | $654.9M | -$1.27B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TEVA // BETA 1.00
ONC // BETA 0.98